Compounds > gefitinib
Page last updated: 2024-09-03

gefitinib and N-[3-(trifluoromethyl)phenyl]-4-quinazolinamine

gefitinib has been researched along with N-[3-(trifluoromethyl)phenyl]-4-quinazolinamine in 1 studies

Compound Research Comparison

Studies
(gefitinib)		Trials
(gefitinib)		Recent Studies (post-2010)
(gefitinib)		Studies
(N-[3-(trifluoromethyl)phenyl]-4-quinazolinamine)		Trials
(N-[3-(trifluoromethyl)phenyl]-4-quinazolinamine)		Recent Studies (post-2010) (N-[3-(trifluoromethyl)phenyl]-4-quinazolinamine)
5,2315662,919703

Protein Interaction Comparison

ProteinTaxonomygefitinib (IC50)N-[3-(trifluoromethyl)phenyl]-4-quinazolinamine (IC50)
Epidermal growth factor receptorHomo sapiens (human)0.5794
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)1.245

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gallus, J; Juvale, K; Wiese, M1

Other Studies

1 other study(ies) available for gefitinib and N-[3-(trifluoromethyl)phenyl]-4-quinazolinamine

ArticleYear
Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2).
    Bioorganic & medicinal chemistry, 2013, Dec-15, Volume: 21, Issue:24

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cells, Cultured; Dogs; Dose-Response Relationship, Drug; Humans; Molecular Structure; Neoplasm Proteins; Quinazolines; Structure-Activity Relationship

2013